Comparison of Micro-dose Human Chorionic Gonadotropin (hCG) With Human Menopausal Gonadotropin (HMG) in Polycystic Ovary Syndrome

Launched by ROYAN INSTITUTE · Jul 27, 2009

Keywords

ClinConnect Summary

Infertile women with PCOS, who have showed resistance to Clomiphen Citrate (150 mg- 5 days) in a previous IUI treatment cycle at Royan Institute (Infertility and Reproductive Medicine Research Centre) will enroll in this prospective randomized clinical trial study and will randomly be divided into three groups.

The study protocol will be assessed by an independent institutional review board and Royan ethics committee. All subjects will be given the written informed consent.

Control group (CC/hMG) will receive the 100 mg CC on days 3 to 7 of that cycle but will receive 150 mg human menopau...

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Women with PCOS diagnosed by the Rotterdam criteria
• • Previously documented dominant follicle or follicles (R12 mm mean diameter) on transvaginal Ultrasound follicular monitoring while receiving CC at the 150-mg dose in our clinic but have failed to ovulate;
• • Primary infertility
• • Documented normal uterine cavity and patent tubes by either hysterosalpingogram or laparoscopy and hysteroscopy;
• • Male partner had to have a normal semen analysis by World Health Organization criteria.
• Exclusion Criteria:
• • previous history of IVF or ICSI treatments.
• • History of hormonal treatment within recent three month (Except OCP, progesterone).
• • History of ovarian cutter or Ovarian drilling.
• • BMI higher than 30.
• • The presence of ovarian cyst (more than 30 mm) during third cycle ultrasound.